Core Viewpoint - Target Hospitality Corp. announced the redemption of all $181.4 million of its 10.75% senior secured notes due 2025, scheduled for March 25, 2025, at a redemption price of 101.000% of the principal amount plus accrued interest [1][2]. Company Overview - Target Hospitality is one of North America's largest providers of vertically integrated modular accommodations and value-added hospitality services, offering a range of solutions including food service management, concierge, laundry, logistics, security, and recreational facilities services [5].

Core Viewpoint - Target Hospitality Corp has entered into a five-year lease and services agreement with CoreCivic to reactivate operations at the Dilley Facility in Texas, which will support up to 2,400 individuals and is expected to generate over $246 million in revenue over its term [1][4][3] Company Overview - Target Hospitality is one of North America's largest providers of vertically integrated modular accommodations and value-added hospitality services, offering a range of solutions including food service management, concierge, laundry, logistics, security, and recreational facilities [8] Contract Details - The Dilley Contract will maintain a similar economic structure to the previous agreement with CoreCivic, including fixed minimum revenue regardless of occupancy, with an anticipated revenue of approximately $30 million in 2025 [4][6] - The Dilley Facility previously operated from September 2014 to August 2024 as the South Texas Family Residential Center, and its reactivation will require no capital investment due to the consistency of the community layout [2][3] Strategic Importance - The reactivation of the Dilley Facility highlights Target's flexible operating model and unique capabilities, positioning the company to respond effectively to customer demand and pursue additional growth opportunities aligned with U.S. government immigration policies [5][6] - The Dilley Contract is supported by an amended intergovernmental services agreement with U.S. Immigration and Customs Enforcement, subject to annual appropriations and potential cancellation with 60 days' notice [7]

Company Overview - Target Hospitality (TH) is expected to report a year-over-year decline in earnings, with a projected EPS of $0.07, reflecting a decrease of 75.9% compared to the previous year [3] - Revenues are anticipated to be $80.1 million, down 36.5% from the same quarter last year [3] Earnings Estimates and Revisions - The consensus EPS estimate has been revised down by 80.77% over the last 30 days, indicating a significant reassessment by analysts [4] - The Most Accurate Estimate for Target Hospitality is lower than the Zacks Consensus Estimate, resulting in an Earnings ESP of -25%, suggesting a bearish outlook from analysts [10][11] Earnings Surprise Prediction - The Zacks Earnings ESP model indicates that a positive or negative reading can predict the likelihood of an earnings beat or miss, with a strong predictor being a positive Earnings ESP combined with a favorable Zacks Rank [8][9] - Target Hospitality currently holds a Zacks Rank of 3 (Hold), making it challenging to predict an earnings beat [11] Historical Performance - In the last reported quarter, Target Hospitality exceeded the consensus EPS estimate of $0.12 by delivering earnings of $0.20, resulting in a surprise of +66.67% [12] - Over the past four quarters, the company has successfully beaten consensus EPS estimates on all occasions [13] Industry Comparison - Vail Resorts (MTN), a peer in the Zacks Leisure and Recreation Services industry, is expected to report an EPS of $6.29, reflecting a year-over-year increase of 9.2% [17] - Vail Resorts' revenues are projected to be $1.14 billion, up 5.6% from the previous year, with an Earnings ESP of 1.64% indicating a likelihood of beating the consensus EPS estimate [18]

Core Viewpoint - Target Hospitality (TH) has experienced significant selling pressure, resulting in a 41.5% decline in stock price over the past four weeks, but analysts anticipate better earnings than previously expected, indicating potential for recovery [1]. Group 1: Technical Indicators - The Relative Strength Index (RSI) is utilized to identify oversold stocks, with a reading below 30 typically indicating oversold conditions [2]. - TH's current RSI reading is 21.07, suggesting that the heavy selling may be exhausting itself and a trend reversal could be imminent [5]. Group 2: Fundamental Indicators - There is a consensus among sell-side analysts that earnings estimates for TH have increased by 1.9% over the last 30 days, which often correlates with price appreciation [6]. - TH holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks, further supporting the potential for a turnaround [7].

Core Insights - Theratechnologies Inc. reported strong financial results for Q4 and FY2024, with a notable increase in revenue and positive Adjusted EBITDA, indicating a solid performance and growth potential in its HIV portfolio and new product lines [3][6][30]. Financial Performance - Q4 2024 revenue reached $25 million, a 6.6% increase from Q4 2023, while annual revenue for FY2024 was $85.9 million, up 5.0% year-over-year [2][30]. - EGRIFTA SV net sales for Q4 2024 were $17.7 million, a 4.2% increase from the previous year, and full-year sales were $60.1 million, reflecting a 12% growth [2][31]. - Trogarzo net sales in Q4 2024 were $7.3 million, a 12.8% increase, but full-year sales decreased by 8.3% to $25.7 million due to competitive pressures [2][32][33]. - Adjusted EBITDA for Q4 2024 was $7.8 million, a 56% increase from Q4 2023, and for FY2024, it reached $20.2 million compared to a negative $2.9 million in FY2023 [3][42]. Operational Highlights - The company secured $75 million in new credit facilities, enhancing its financial flexibility and supporting its growth strategy [3][10]. - A temporary supply disruption for EGRIFTA SV was resolved, allowing the company to resume distribution and meet market demand [5][48]. - The FDA has set a PDUFA action date of March 25, 2025, for the updated F8 formulation of tesamorelin, which could replace the current formulation [9]. Strategic Developments - The company in-licensed two new investigational drugs, olezarsen and donidalorsen, to drive long-term growth in Canada [11][60]. - Theratechnologies is actively seeking a partner for its oncology program to advance its novel peptide drug conjugates [4][12]. Cost Management - R&D expenses for FY2024 decreased significantly to $17 million from $30.4 million in FY2023, primarily due to reduced spending on various programs [35]. - Selling expenses for FY2024 were $25.4 million, down from $26.8 million in FY2023, reflecting tighter expense control [38]. Financial Position - As of November 30, 2024, the company had cash and cash equivalents totaling $19.8 million, down from $40.4 million a year earlier, indicating a need for careful cash flow management [53]. - The company reported a net loss of $8.3 million for FY2024, an improvement from a loss of $24 million in FY2023 [44].

Core Viewpoint - The U.S. government intends to terminate the Pecos Children's Center services agreement with Target Hospitality's nonprofit partner, effective around February 21, 2025, impacting the company's operations and financial outlook [1][2][5]. Group 1: Contract Termination - The Pecos Children's Center services agreement (PCC Contract) provided facility and hospitality solutions for up to 6,000 individuals, and the nonprofit partner has notified Target of its intention to terminate this contract [2]. - The termination of the PCC Contract allows the company to retain ownership of its modular assets, which can still be utilized for other customer demands and growth opportunities [3]. Group 2: Growth Opportunities - Target Hospitality is actively re-marketing its modular assets and exploring a pipeline of growth opportunities, particularly in relation to U.S. government immigration policies [4]. - The company plans to provide operational and financial updates in light of the contract termination, indicating a shift in its financial outlook for 2025 [5]. Group 3: Company Overview - Target Hospitality is one of North America's largest providers of vertically integrated modular accommodations and hospitality services, offering a range of value-added solutions including food service management and logistics [6].

MONTREAL, Feb. 14, 2025 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a specialty biopharmaceutical company focused on the commercialization of innovative therapies that have the potential to redefine standards of care, today announced the Company will report financial results and provide a business update for its fourth quarter and full year fiscal 2024 ended November 30 on Wednesday, February 26, 2025, at 8:30 a.m. ET. The call will be hosted b ...

Core Insights - Theratechnologies Inc. has resumed distribution of EGRIFTA SV (tesamorelin for injection) after receiving approval from the U.S. FDA for two recently manufactured batches, with immediate shipment to pharmacies [1][2] - The company emphasizes its commitment to providing EGRIFTA SV to individuals with HIV and appreciates the FDA's collaboration in this process [2] - The FDA's review of the Company's Prior Approval Supplement is ongoing, with an action goal date set for April 18, 2025 [2] Company Overview - Theratechnologies is a specialty biopharmaceutical company focused on the commercialization of innovative therapies aimed at redefining standards of care [3] - The company is publicly traded on both the TSX and NASDAQ under the ticker symbols TH and THTX, respectively [3]

Company Overview - Theratechnologies is a biopharmaceutical company focused on developing and commercializing innovative therapies for unmet medical needs [2] - The company is publicly traded on the TSX (TH) and NASDAQ (THTX) [2] Product Situation - EGRIFTA SV (tesamorelin for injection) is the only FDA-approved medicine of its kind for people with HIV [1] - A shortage of EGRIFTA SV will occur at the patient level in mid-January 2025 due to a voluntary shutdown of the contract manufacturing facility in 2024 [4] - Some pharmacies in the United States still have remaining inventory, but several have reported stockouts [4] Regulatory Process - Theratechnologies filed a Prior Approval Supplement (PAS) with the FDA on December 18, 2024 [5] - The company submitted questions regarding two recently manufactured batches of EGRIFTA SV waiting to be released [5] - FDA confirmed it will respond to the company's questions in writing by February 8, 2025 [5] Forward-Looking Statements - The company expects FDA to provide answers to its questions by February 8, 2025 [8] - Assumes current market demand for EGRIFTA SV will remain unaffected [8] - Believes the shortage will not adversely impact the company's financial conditions [8] - Anticipates being able to negotiate waivers of defaults with secured creditors if needed [8]

THE WOODLANDS, Texas, Dec. 30, 2024 /PRNewswire/ -- Target Hospitality Corp. ("Target Hospitality," "Target" or the "Company") (Nasdaq: TH), one of North America's largest providers of vertically integrated modular accommodations and value-added hospitality services, today announced the hiring of Brendan Dowhaniuk as Executive Vice President of Strategy and Corporate Development. Mr. Dowhaniuk will be responsible for advancing the Company's key strategic priorities, including mergers and acquisitions, and f ...